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Evaluating drug targets through human 
loss-of-function genetic variation
Eric Vallabh Minikel1,2,3,4,5,6,7,8 ✉, Konrad J. Karczewski1,4, Hilary C. Martin9,  
Beryl B. Cummings1,4,5, Nicola Whiffin1,10, Daniel Rhodes11, Jessica Alföldi1,4,  
Richard C. Trembath12, David A. van Heel13, Mark J. Daly1,4, Genome Aggregation Database 
Production Team*, Genome Aggregation Database Consortium*, Stuart L. Schreiber3,14 & 
Daniel G. MacArthur1,4,153,154 ✉
Naturally occurring human genetic variants that are predicted to inactivate 
protein-coding genes provide an in vivo model of human gene inactivation that 
complements knockout studies in cells and model organisms. Here we report three 
key findings regarding the assessment of candidate drug targets using human 
loss-of-function variants. First, even essential genes, in which loss-of-function 
variants are not tolerated, can be highly successful as targets of inhibitory drugs. 
Second, in most genes, loss-of-function variants are sufficiently rare that 
genotype-based ascertainment of homozygous or compound heterozygous 
‘knockout’ humans will await sample sizes that are approximately 1,000 times those 
presently available, unless recruitment focuses on consanguineous individuals. 
Third, automated variant annotation and filtering are powerful, but manual curation 
remains crucial for removing artefacts, and is a prerequisite for recall-by-genotype 
efforts. Our results provide a roadmap for human knockout studies and should guide 
the interpretation of loss-of-function variants in drug development.
Human genetics is an increasingly crucial source of evidence guiding 
the selection of new targets for drug discovery1. Most new clinical drug 
candidates eventually fail for lack of efficacy2, and although in vitro, 
cell culture and animal model systems can provide preclinical evidence 
that the compound engages its target, too often the target itself is not 
causally related to human disease1. Candidates targeting genes with 
human genetic evidence for disease causality are more likely to reach 
approval3,4, and identification of humans with loss-of-function (LoF) 
variants, particularly two-hit (homozygous or compound heterozy-
gous) genotypes, has, for several genes, correctly predicted the safety 
and phenotypic effect of pharmacological inhibition5. Although these 
examples demonstrate the value of human genetics in drug develop-
ment, important questions remain regarding strategies for identifying 
individuals with LoF variants in a gene of interest, interpretation of 
the frequency—or lack—of such individuals, and whether it is wise to 
pharmacologically target a gene in which LoF variants are associated 
with a deleterious phenotype.
Public databases of human genetic variation have catalogued pre-
dicted loss-of-function (pLoF) variants—nonsense, essential splice site, 
and frameshift variants expected to result in a non-functional allele. 
This presents an opportunity to study the effects of pLoF variation in 
genes of interest and to identify individuals with pLoF genotypes to 
understand gene function or disease biology, or to assess potential 
for therapeutic targeting. Although many variants initially annotated 
as pLoF do not, in fact, abolish gene function6, rigorous automated 
filtering can remove common error modes7. True LoF variants are gen-
erally rare, and show important differences between outbred, bottle-
necked8 and consanguineous9 populations6,10. Counting the number 
of distinct pLoF variants in each gene in a population sample allows the 
quantification of gene essentiality in humans through a metric named 
‘constraint’10–13. Specifically, the rate at which de novo pLoF mutations 
arise in each gene is predicted on the basis of rates of DNA mutation10,12, 
and the ratio of the count of pLoF variants observed in a database to 
the number expected based on mutation rates—obs/exp, or constraint 
score—measures how strongly purifying natural selection has removed 
such variants from the population. The annotation of pLoF variants 
remains imperfect, and continued improvements are being made14, 
but constraint usefully measures gene essentiality, as demonstrated 
by agreement with cell culture and mouse knockout experiments7, by 
overlap with human disease genes7,10 and genes depleted for structural 
variation15, and by the power of constraint to enrich for deleterious 
variants in neurodevelopmental disorders7,16.
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Building on these insights, here we leverage pLoF variation in the 
Genome Aggregation Database (gnomAD)7 v2 dataset of 141,456 indi-
viduals to answer open questions in the interpretation of human pLoF 
variation in disease biology and drug development.
Constraint in human drug targets
We compared constraint in the targets of approved drugs extracted 
from DrugBank17 (n = 383) versus all protein-coding genes (n = 17,604). 
Drug targets were, on average, just slightly more constrained than all 
genes (mean 44% versus 52%, nominal P = 0.00028, D = 0.11, two-sided 
Kolmogorov–Smirnov test), but the two gene sets had a qualitatively 
similar distribution of scores, ranging from intensely constrained 
(0% obs/exp) to not at all constrained (≥100% obs/exp) (Fig. 1a). Con-
straint scores showed clear divergence between categories of genes 
(Extended Data Table 1) expected to be more or less tolerant of inacti-
vation (Fig. 1b), as previously reported7,10, validating the usefulness of 
constraint as a measure of gene essentiality. Nonetheless, when drug 
targets were stratified by drug effect (Fig. 1b), modality, or indication 
(Extended Data Fig. 1), no statistically significant differences between 
subsets of drug targets were observed.
The slightly but significantly lower obs/exp value among drug targets 
may superficially appear to provide evidence that constrained genes 
make superior drug targets. Stratification of drug targets by protein 
family, human disease association, and tissue expression, however, 
argues against this interpretation. Drug targets are strongly enriched 
for a few canonically ‘druggable’ protein families, for genes known 
to be involved in human disease, and for genes with tissue-restricted 
expression; each of these properties is in turn correlated with either 
significantly stronger or weaker constraint (Extended Data Fig. 2). 
Although controlling for these correlations does not abolish the trend 
of stronger constraint among drug targets, the correlation of so many 
observed variables with the status of a gene as a drug target argues that 
many unobserved variables probably also confound interpretation of 
the lower mean obs/exp value among drug targets.
The overall constraint distribution of drug targets (Fig. 1a) also 
argues against the view that a gene in which LoF is associated with a 
deleterious phenotype cannot be successfully targeted. Indeed, 19% 
of drug targets (n = 73), including 52 targets of inhibitors, antagonists 
or other ‘negative’ drugs, have lower obs/exp values than the average 
(12.8%) for genes known to cause severe diseases of haploinsufficiency18 
(ClinGen level 3). To determine whether this finding could be explained 
by a particular class or subset of drugs, we examined constraint in sev-
eral well-known example drug targets (Fig. 1c, Extended Data Table 2). 
Some heavily constrained genes are targets of cytotoxic chemotherapy 
agents such as topoisomerase inhibitors or cytoskeleton disruptors, 
a set of drugs intuitively expected to target essential genes. However, 
genes with near-complete selection against pLoF variants also include 
HMGCR and PTGS2, the targets of highly successful, chronically used 
inhibitors—statins and aspirin.
These human in vivo data further the evidence from other species 
and models that essential genes can be good drug targets. Homozy-
gous knockout of Hmgcr and Ptgs2 are lethal in mice19–21. Drug targets 
exhibit higher inter-species conservation than other genes22. Targets 
of negative drugs include 14 genes with lethal heterozygous knockout 
mouse phenotypes reported23 and 6 reported as essential in human 
cell culture24.
Prospects for finding human ‘knockouts’
Athough constraint alone is not adequate to nominate or exclude 
drug targets, the study of individuals with single hit (heterozygous) 
or two-hit (‘knockout’) LoF genotypes in a gene of interest can be highly 
informative about the biological effect of engaging that target5. To 
assess prospects for ascertaining knockout individuals, we computed 
the cumulative allele frequency (CAF) of pLoF variants in each gene 
(Methods), and then used this to estimate the expected frequency of 
two-hit individuals under different population structures (Fig. 2) in 
the absence of natural selection.
Whereas gnomAD is now large enough to include at least one pLoF 
heterozygote for most (15,317 out of 19,194; 79.8%) genes, ascertain-
ment of total knockout individuals in outbred populations will require 
1,000-fold larger sample sizes for most genes: the median expected 
two-hit frequency of a gene is just six per billion (Fig. 2a). Even if every 
human on Earth were sequenced, there are 4,728 genes (24.6%) for 
which identification of even one two-hit individual would not be 
expected in outbred populations. Intuitively, because the sample size 
of gnomAD today is larger than the square root of the world population, 
variants so far seen in zero or only a few heterozygous individuals are 
not likely to ever be seen in a homozygous state in outbred popula-
tions, except where variants prove common in populations not yet 
well-sampled by gnomAD.
Because population bottlenecks can result in very rare variants 
present in a founder rising to an unusually high frequency, we also 
considered knockout discovery in bottlenecked populations, using 
Finnish individuals in gnomAD as an example8. Although this popula-
tion structure can enable well-powered association studies for the small 
fraction of genes in which pLoF variants drifted to high frequency due 
to the bottleneck, overall, identification of two-hit pLoF individuals 
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TOP1 Topoisomerase I inhibitors
CHRM1 M1-selective antimuscarinics
TUBB Cytoskeleton disruptors
PTGS2 Non-steroidal anti-inammatory drugs
HMGCR Statins
PDE5A Phosphodiesterase 5 inhibitors
DHFR Antifolates
ATP4A Proton pump inhibitors
P2RY12 Antiplatelets
HRH1 H1 antihistamines
ACE Angiotensin-converting enzyme inhibitors
PCSK9 Cholesterol-lowering antibodies
c
Fig. 1 | pLoF constraint in drug targets. a, Histogram of pLoF obs/exp values 
for all genes (black, n = 17,604) versus drug targets (blue, n = 383). b, Forest plot 
of means (dots) and 95% confidence intervals of the mean (line segments), for 
constraint in the indicated gene sets (data sources and n values in Extended 
Data Table 1). For drug effect, ‘positive’ indicates agonist, activator or inducer, 
whereas negative indicates antagonist, inhibitor or suppressor, for example.  
c, Examples of drug targets and corresponding drug classes from across the 
constraint spectrum. Details in Extended Data Table 2.
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for a pre-specified gene of interest appears equally or more difficult 
in Finnish individuals than in outbred populations (Fig. 2b, Extended 
Data Fig. 3), because rare variants not present in a founder have been 
effectively removed from the population.
In consanguineous individuals, parental relatedness greatly increases 
the frequency of homozygous pLoF genotypes. The n = 2,912 individuals 
in the East London Genes & Health (ELGH) cohort25 who report hav-
ing parents who are second cousins or closer have on average 5.8% of 
their genomes autozygous. Here, the expected frequency of two-hit 
individuals is many times higher than in outbred populations, at five 
per million for the median gene (Fig. 2c).
These projections allow us to draft a roadmap for discovery of human 
knockouts across 19,194 genes (Fig. 2d, e). Online Mendelian Inheritance 
in Man (OMIM) already describes human disease association for 3,367 
genes (18%), although the discovery of LoF individuals in population 
databases will still be valuable for assessing penetrance and identifying 
LoF syndromes of known gain-of-function genes. Another 3,421 genes 
(18%) without known human disease association have two-hit pLoF 
genotypes reported in gnomAD7, ELGH26, PROMIS27, deCODE28 or UK 
Biobank29, which suggests that this genotype may be tolerated. An addi-
tional 2,190 genes (11%) appear intolerant of heterozygous inactivation 
(pLI score > 0.9) in gnomAD—a set expected to be enriched for genes 
with severe heterozygous and lethal homozygous LoF phenotypes. 
Another 2,781 genes (14%) have no pLoF variants observed in gnomAD, 
but our sample size is not yet large enough to robustly infer LoF intol-
erance. For these genes, observation of outbred two-hit individuals is 
not expected, and we cannot yet assess the feasibility of identifying 
consanguineous two-hit individuals because we lack an estimate of 
pLoF allele frequency.
This leaves 7,435 genes (39%) for which one or more pLoFs are 
observed in gnomAD, but strong LoF intolerance cannot be deter-
mined, two-hit genotypes have not been observed, and a human disease 
phenotype is not known. We projected the sample sizes required to 
identify knockout individuals for these genes (Fig. 2e). In outbred popu-
lations, current sample sizes would need to increase by approximately 
1,000-fold before ascertainment of a single two-hit LoF individual 
would be expected for the typical gene. By contrast, around a 10- to 
100-fold increase from current consanguineous sample size, meaning 
hundreds of thousands of individuals in absolute terms, would identify 
at least one two-hit LoF individual for the typical gene. Among other 
simplifying assumptions (Methods), these projections presume that 
complete knockout is tolerated. When only one or a few two-hit indi-
viduals are expected in a dataset, the absence of any such individuals 
can be due to either early lethality, a severe clinical phenotype incom-
patible with inclusion in gnomAD, or simply chance. Thus, the ability 
to infer lethality of the two-hit genotype based on statistical evidence 
will lag behind the identification of two-hit individuals where they 
do exist (Fig. 2e). For some genes, inference of lethality will always 
remain impossible in outbred populations, though it may be feasible 
in consanguineous individuals.
Curation of pLoF variants
Where pLoF variants can be identified, they are a valuable resource for 
assessing the effect of lifelong reduction in gene dosage. To highlight 
the challenges and opportunities of identifying such variants, we manu-
ally curated gnomAD data and the scientific literature for six genes 
associated with gain-of-function (GoF) neurodegenerative diseases, 
for which inhibitors or suppressors are under development30–35: HTT 
(Huntington's disease), MAPT (tauopathies), PRNP (prion disease), 
SOD1 (amyotrophic lateral sclerosis), and LRRK2 and SNCA (Parkinson's 
disease). The results (Fig. 3, Extended Data Table 3) illustrate four points 
about pLoF variant curation.
First, other things being equal, genes with longer coding sequences 
offer more opportunities for LoF variants to arise, and so tend to 
have a higher cumulative frequencies of LoF variants, unless they are 
heavily constrained. Ascertainment of LoF individuals is thus harder 
for shorter and/or more constrained genes, even though these may 
be good targets.
Second, many variants annotated as pLoF are false positives6, and 
these are enriched for higher allele frequencies, so that both filtering 
and curation have an outsized effect on the cumulative allele frequency 
of LoF. Studies of human pLoF variants lacking stringent curation can 
therefore easily dilute results with false pLoF carriers.
Third, after careful curation, cumulative LoF allele frequency is 
sometimes sufficiently high to place certain bounds on what heterozy-
gote phenotype might exist. For example, GoF mutations causing 
genetic prion disease have a genetic prevalence of approximately 1 
in 50,00036 and have been known for three decades, with thousands 
of cases identified, making it unlikely that a comparably severe and 
penetrant haploinsufficiency syndrome associated with PRNP would 
have gone unnoticed to the present day despite being more than twice 
as common (roughly 1 in 18,000). Similar arguments can be made for 
HTT, LRRK2 and SOD1 genes (Extended Data Tables 3, 4). Of course, 
this does not rule out a less severe or less penetrant heterozygous 
LoF phenotype.
Finally, careful inspection of the distributions of pLoF variants 

















































































2-hit LoF expected if non-lethal
Lethality inferrable if not observed
e
association known
Fig. 2 | Prospects for discovery of human knockouts. a–c, Histograms (a–c): 
genes by expected heterozygote frequency (orange), and two-hit homozygote and 
compound heterozygote frequency (purple). a, Outbred populations. b, Finnish 
individuals; an example of a bottlenecked population. c, Consanguineous 
individuals. d, Current status of pLoF or disease association discovery for all 
protein-coding genes. e, Projected sample sizes required for discovery of two-hit 
individuals (solid lines) and for statistical inference that a two-hit genotype is lethal 
if no such individuals are observed (dashed lines), for ‘pLoF observed in gnomAD’ 
genes (d) for consanguineous and outbred individuals.
462 | Nature | Vol 581 | 28 May 2020
Analysis
and PRNP genes each have different non-random positional distri-
butions of pLoF variants (Fig. 3). High-frequency HTT pLoF variants 
cluster in the polyglutamine/polyproline repeat region of exon 1 and 
appear to be alignment artefacts (Fig. 3a). True HTT LoF variants are 
rare and the gene is highly constrained, which might suggest some 
fitness effect in a heterozygous state in addition to the known severe 
homozygous phenotype37,38, although the frequency of LoF carriers 
still argues against a penetrant syndromic illness, consistent with 
the lack of phenotype reported in heterozygotes identified so far38,39. 
High-frequency MAPT pLoF variants cluster in exons not expressed in 
the brain in GTEx data14,40, and all remaining pLoFs appear to be align-
ment or annotation errors (Fig. 3b). No true LoFs are observed in MAPT, 
although our sample size is insufficient to prove that MAPT LoF is not 
tolerated—among constitutive brain-expressed exons, we expect 12.6 
LoFs and observe 0, giving a 95% confidence interval upper bound of 
23.7% for obs/exp values. PRNP-truncating variants in gnomAD cluster 
in the N terminus; the sole C-terminal truncating variant in gnomAD 
is a dementia case (Extended Data Table 5), consistent with variants 
at codon ≥145 causing a pathogenic gain-of-function through change 
in localization (Fig. 3c). Within codons 1–144, PRNP is unconstrained 
(Extended Data Table 3), and no neurological phenotype has been 
identified in individuals with truncating variants so far, consistent 
with the hypothesis that N-terminal truncating variants are true LoF 
and are tolerated in a heterozygous state41.
Discussion
Studying human gene inactivation can illuminate human biology 
and guide the selection of drug targets, complementing mouse knockout 
studies42, but analysis of any one gene requires genome-wide context to 
set expectations and guide inferences. Here we have used gnomAD data 
to provide context to aid in the interpretation of human LoF variants.
Targets of approved drugs range from highly constrained to completely 
unconstrained. There may be several reasons why some genes apparently 
tolerate pharmacological inhibition but not genetic inactivation. LoF 
variants in constitutive exons should affect all tissues for life, whereas 
drugs differ in tissue distribution and timing and duration of use. Many 
drugs known or suspected to cause fetal harm are tolerated in adults43, 
and might target developmentally important genes. Constraint is thought 
to primarily reflect selection against heterozygotes13, the effective gene 
dosage of which may differ from that achieved by a drug. Constraint meas-
ures natural selection over centuries or millennia; the environment of our 
ancestors presented different selective pressures from what we face today. 
Actions of small-molecule drugs may not map one-to-one onto genes44–47. 
Regardless, these human in vivo data show that even a highly deleterious 
knockout phenotype is compatible with a gene being a viable drug target.
For most genes, the lack of total knockout individuals identified so 
far does not yet provide statistical evidence that this genotype is not 
tolerated. Indeed, for many genes, such evidence may never be attain-
able in outbred populations. Bottlenecked populations, individually, 
are unlikely to yield two-hit individuals for a pre-specified gene of inter-
est, although the sequencing of many different, diverse bottlenecked 
populations will certainly expand the set of genes accessible by this 
approach. Identification of two-hit individuals will be most greatly 
aided by increased investment in consanguineous cohorts, in which the 
sample size required for any given gene is often orders of magnitude 
lower than in outbred populations. Our analysis is limited by sample 
size, insufficient diversity of sampled populations, and simplifying 
assumptions about population structure and distribution of LoF vari-
ants, so our calculations should be taken as rough, order-of-magnitude 
estimates. Nonetheless, this strategic roadmap for the identification 
of human knockouts should inform future research investments and 
rationalize the interpretation of existing data.
Recall-by-genotype efforts are only valuable if the variants in ques-
tion are correctly annotated. Automated filtering7 and transcript 
expression-aware annotation14 are powerful tools, but we demonstrate 
the continued value of manual curation for excluding further false posi-
tives, assessing and interpreting the cumulative allele frequency of true 
LoF variants, and identifying error modes or biological phenomena that 
give rise to non-random distributions of pLoF variants across a gene. 
Such curation is essential before any recontact efforts, and establish-
ing methods for high-throughput functional validation48 of LoF vari-
ants is a priority. Our curation of pLoF variants in neurodegenerative 
disease genes is limited by a lack of functional validation and detailed 
phenotyping; a companion paper demonstrates a deeper investigation 
of the effects of LoF variants in the LRRK2 gene49.
Drug development projects may increasingly be accompanied by 
efforts to phenotype human carriers of LoF variants. With the cost of 
drug discovery driven overwhelmingly by failure50, successful interpre-
tation of LoF data to select the right targets and right clinical pathways 
will yield outsize benefits for research productivity and, ultimately, 
human health.
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Fig. 3 | Insights from non-random positional distributions of pLoF variants. 
a–c, HTT (a), MAPT, with brain expression data from GTEx40 (b) and PRNP, a 
single protein-coding exon with domains removed by post-translational 
modification in grey (c), showing previously reported variants41 and those 
newly identified in gnomAD and in the literature (Extended Data Table 5). GPI, 
glycosylphosphatidylinositol. Detailed variant curation results are provided in 
Supplementary Table 1.
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Methods
No statistical methods were used to predetermine sample size. The 
experiments were not randomized, and investigators were not blinded 
to allocation during experiments and outcome assessment.
Data sources
pLoF analyses used the gnomAD dataset of 141,456 individuals7. For data 
consistency, all genome-wide constraint and CAF analyses used only the 
125,748 gnomAD exomes. Curated analyses of individual genes used all 
141,456 individuals including 15,708 whole genomes. Gene lists used in 
this study were extracted from public data sources between September 
2018 and June 2019. Data sources and criteria for gene list extraction 
are shown in Extended Data Table 1. This study was performed under 
ethical approval from the Partners Healthcare Institutional Research 
Board (2013P001339/MGH) and the Broad Institute Office of Research 
Subjects Protection (ORSP-3862). All research participants provided 
informed consent.
Calculation of pLoF constraint
The calculation of constraint values for genes has been described in 
general elsewhere10,12 and for this dataset specifically by Karczewski 
et al.7. Constraint calculations used LOFTEE-filtered (‘high confi-
dence’) single-nucleotide variants (which for pLoF means nonsense 
and essential splice site mutations) found in gnomAD exomes with 
minor allele frequency <0.1%. Only unique canonical transcripts for 
protein-coding genes were considered, yielding 17,604 genes with 
available constraint values. For curated genes (Extended Data Table 2), 
the number of observed variants passing curation was divided by the 
expected number of variants to yield a curated constraint value. For 
PRNP, the expected number of variants was adjusted by multiplying 
by the ratio of the sum of mutation frequencies for all possible pLoF 
variants in codons 1–144 to the sum of mutation frequencies for all 
possible pLoF variants in the entire transcript, yielding 6 observed 
out of 6.06 expected. For MAPT, the expected number of variants was 
taken from Ensembl transcript ENST00000334239, which includes 
only the exons identified as constitutively brain-expressed in Fig. 3b 
(exon numbering previously described51).
Calculation of pLoF heterozygote and homozygote/compound 
heterozygote frequencies
LOFTEE-filtered high-confidence pLoF variants with minor allele fre-
quency <5% in 125,748 gnomAD exomes were used to compute the 
proportion of individuals without a loss-of-function variant (q); the 
CAF was computed as p = 1 − sqrt(q). This approach conservatively 
assumes that, if an individual has two different pLoF variants, they are 
in cis to each other and count as only one pLoF allele.
For outbred populations (Fig. 2a), we used the value of p from all 
125,748 gnomAD exomes, as this allows the largest possible sample 
size. This includes some individuals from bottlenecked populations, 
for which the distribution of p does differ from outbred populations, 
but these individuals are a small proportion of gnomAD exomes (12.6%). 
This also includes some consanguineous individuals, but these are an 
even smaller proportion of gnomAD exomes (2.3%), and any difference 
in the value of p between consanguineous and outbred populations is 
expected to be very small. Heterozygote frequency was calculated as 
2p(1 −p) and homozygote and compound heterozygote frequency was 
calculated as p2. Lines indicate the size of gnomAD (141,456 individuals) 
and the world population (6.69 billion).
For bottlenecked populations (Fig. 2b), we used the value of p from 
the 10,824 Finnish exomes only. Lines indicate the number of Finn-
ish individuals in gnomAD (12,526) and the population of Finland 
(5.5 million).
For consanguineous individuals (Fig. 2c), we again used the value of 
p from all gnomAD exomes, because p is not expected to differ greatly 
in consanguineous versus outbred populations. We used the mean 
proportion of the genome in runs of autozygosity (a) from individuals 
self-reporting second cousin or closer parents in East London Genes 
& Health, a = 0.05766 (rounded to 5.8%). Heterozygote frequency was 
calculated as 2p(1 − p) and homozygote and compound heterozygote 
frequency was calculated as (1 − a)p2 + ap. Lines indicate the number 
of consanguineous South Asian individuals in gnomAD (n = 2,912, by 
coincidence the same number as report second cousin or closer parents 
in ELGH) based on F > 0.05 (a conservative estimate, because second 
cousin parents are expected to yield F = 0.015625), and the estimated 
number of individuals in the world with second cousin or closer parents 
(10.4% of the world population)9.
Several caveats apply to our CAF analysis. First, our approach naively 
treats genes with no pLoFs observed as having P = 0, even though pLoFs 
might be discovered at a larger sample size. Second, we naively group 
all populations together, even though the distribution of populations 
sampled in gnomAD does not reflect the world population7; we believe 
that this is reasonable because CAF for many genes is driven by single-
tons and other ultra-rare variants for which frequency is not expected to 
differ appreciably by continental population10. (It is important to note 
that the histograms shown in Fig. 2 reflect the expected frequency of 
heterozygotes and homozygotes/compound heterozygotes, based on 
gnomAD allele frequency, rather than the actual observed frequency 
of individuals with these genotypes in gnomAD.) Third, we use only 
protein-truncating variants annotated as pLoF in gnomAD. Structural 
and non-coding variation resulting in a loss of function may be missed 
in exomes, and missense variants resulting in a loss of function cannot 
be rigorously annotated. Fourth, we naively treat genes with one pLoF 
allele observed as having P = 1/(2 × 125,748), even though on average 
singleton variants have a true allele frequency lower than their nominal 
allele frequency10. Fifth, the variants included in this analysis are filtered 
but have not been manually curated or functionally validated, so some 
will ultimately prove not to be true LoF. These false positives tend to 
be more common and will have disproportionately contributed to the 
cumulative LoF allele frequency. Sixth, as described in the main text, 
our calculations assume that complete knockout is tolerated, which 
will not be true for some genes. We therefore also include a projection 
of the sample size needed to infer lethality from the absence of two-hit 
knockout individuals (Fig. 2e). Points one to three will tend to lead to 
underestimation of the true complete knockout frequency, whereas 
points four to six will tend to lead to overestimation. On balance, our 
calculations may reflect an upper bound of complete knockout fre-
quency for most genes owing to the strong influence of factors five and 
six. Finally, as a matter of comparison between population structures, 
the sample size for all gnomAD exomes (Fig. 2a, c) is larger than for 
only Finnish exomes (Fig. 2b). For a version of Fig. 2 with the global 
gnomAD population downsampled to the same sample size as the 
gnomAD Finnish population, see Extended Data Fig. 2.
Knockout roadmap
For the knockout ‘roadmap’ (Fig. 2d, e), we classified genes according 
to the current status of human disease association and LoF ascertain-
ment. Genes were classified as having a Mendelian disease association 
if they were present in OMIM with the filters described in Extended 
Data Table 1.
Remaining genes were classified as ‘2-hit LoF reported’ based on 
presence in one or more of the following gene lists: homozygous 
LoF genotypes in gnomAD curated as previously described7; filtered 
homozygous LoF genotypes in runs of autozygosity with minor allele 
frequency <1% in canonical transcripts in the Bradford, Birmingham 
and ELGH25 cohorts (total n = 8,925); observed number of imputed 
homozygotes >1 or number of compound heterozygous carriers where 
minor allele frequency <2% (for both variants) in deCODE28; homozy-
gous LoF reported in PROMIS27; homozygous LoF with minor allele 
frequency <1% in UK Biobank29.
Analysis
The remainder of genes were sequentially classified as ‘likely haplo-
insufficient’ if pLI >0.9 in gnomAD, ‘pLoF not yet observed’ if CAF = 0 in 
gnomAD, and, finally, ‘pLoF observed in gnomAD’ if CAF >0 in gnomAD.
Genetic prevalence estimation
Here, we define ‘genetic prevalence’ for a given gene as the proportion 
of individuals in the general population at birth who have a patho-
genic variant in that gene that will cause them to later develop disease. 
Genetic prevalence has not been well-studied or estimated for most 
disease genes.
In principle, it should be possible to estimate genetic prevalence 
simply by examining the allele frequency of reported pathogenic vari-
ants in gnomAD. In practice, three considerations usually preclude this 
approach. First, the present gnomAD sample size of 141,456 exomes 
and genomes is still too small to permit accurate estimates for very rare 
diseases. Second, the mean age of gnomAD individuals is approximately 
55, which is above the age of onset for many rare genetic diseases, and 
individuals with known Mendelian disease are deliberately excluded, 
so pathogenic variants will be depleted in this sample relative to the 
whole birth population. Third and most importantly, a large fraction of 
reported pathogenic variants lack strong evidence for pathogenicity 
and are either benign or low penetrance10,41, so without careful cura-
tion of pathogenicity assertions, summing the frequency of reported 
pathogenic variants in gnomAD will in most cases vastly overestimate 
the true genetic prevalence of a disease.
Instead, we searched the literature and very roughly estimated 
genetic prevalence based on available data. In most cases, we took 
disease incidence (new cases per year per population), multiplied by 
proportion of cases due to variants in a gene of interest, and multiplied 
by average age at death in cases. In some cases, estimates of at-risk 
population or direct measures of genetic prevalence were available. 
Details of the calculations undertaken for each gene are provided in 
Extended Data Table 4.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
The gnomAD v2 data are available via the gnomAD browser (https://
gnomad.broadinstitute.org).
Code availability
Additional data and the R 3.5.1 and Python 2.7.10 source code for 
this study are available via GitHub (https://github.com/ericminikel/
drug_target_lof).
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Extended Data Fig. 1 | Drug target constraint by modality and indication. 
Mean (dots) and 95% confidence interval (line segments) for constraint in 
subsets of drug-targets sets (data sources and number of genes for each list are 
provided in Extended Data Table 1). Modality information was extracted from 
DrugBank and indication information from ATC codes; see Extended Data 
Table 1 for details.
Extended Data Fig. 2 | Drug-target gene set confounding. a, Forest plot of 
means (dots) and 95% confidence intervals of the mean (line segments) for gene 
sets evaluated for confounding with drug-target status. Data sources and 
number of genes for each list are provided in Extended Data Table 1. LoF  
obs/exp ratios differ significantly from the set of all genes for four canonically 
druggable protein families (top), human disease-associated genes (middle), 
and genes by broadness of tissue expression (bottom). Within each class,  
the genes that are drug targets have a lower mean obs/exp ratio (hollow  
grey circles) than the class overall. b, The druggable protein families, 
disease-associated genes, and genes expressed in some tissues but not others 
are enriched several-fold among the set of drug targets. Bars indicate fold 
enrichment and error bars indicate 95% confidence intervals.  
c–e, Composition of drug targets when broken down by protein family (c), 
disease association (d), or broadness of tissue expression (e). The enriched 
classes account for most drug targets. In a linear model, after controlling for 
protein family, disease association status, and number of tissues with 
expression >1 transcript per million (TPM), drug targets are still more 
constrained than other genes (−8.0% obs/exp, nominal P = 0.00011, t = −3.9, 
df = 17,325 for the contribution of drug_target in the linear regression  
obs/exp ~ drug_target + family + dz_assoc + n_tissues), but the probable 
existence of additional unobserved confounders cautions against 
over-interpretation of this observation (see main text).
Analysis
Extended Data Fig. 3 | Expected frequency of individuals with one or two 
null alleles for every protein-coding gene across different population 
models, with sample size held constant. This is identical to Fig. 2 except as 
follows. As noted in the Methods, one caveat about Fig. 2 is that the sample size 
is larger for the plots using all gnomAD exomes (Fig. 2a, c) than for Finnish 
exomes (Fig. 2b). This figure shows the same analysis, but with the global 
gnomAD population downsampled to 10,824 randomly chosen exomes so that 
the same size is identical to that of Finnish exomes. Computation of 
P = 1 − sqrt(q) as described in the Methods is computationally expensive for 
downsampled datasets because it requires individual-level genotypes. Instead, 
this analysis uses ‘classic’ CAF, which is simply the sum of allele frequencies of 
all high-confidence pLoF variants each at allele frequency <5%, capped at a 
total of 100%, for both global and Finnish exomes. The results show that even 
when the sample size is held constant, the number of genes with zero pLoF 
variants observed is higher in a bottlenecked population than in a mostly 
outbred population. A constant y axis with no axis breaks is used in this figure 
to make this difference more clearly visible.
Extended Data Table 1 | Data sources for gene lists used in this study
For analysis, only protein-coding genes with unambiguous mapping to current approved gene symbols were used; numbers in the table reflect this. Values in the N column indicate totals from 
the full universe of 19,194 genes; values in the N* column indicate the subset of genes with non-missing constraint values, used for Fig. 1 and Extended Data Figs. 1, 2. The following references 
are cited in the table: refs. 17,18,23,24,40,52–57.
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Extended Data Table 2 | Spectrum of tolerance to genetic inactivation among human drug targets
Example targets are arranged from the most intolerant (top) to the most tolerant (bottom) of inactivation.
Extended Data Table 3 | Curation of pLoF variation in six neurodegenerative disease genes
Shown are the coding sequence length (base pairs, bp), constraint value (pLoF obs/exp) after filtering and curation, cumulative allele frequency before and after filtering and manual curation, 
estimated frequency of true pLoF heterozygotes in the population, and genetic prevalence (population frequency including pre-symptomatic individuals) of the GoF disease associated with 
the gene. Genetic prevalence calculations are described in Extended Data Table 4, and variant curation details are provided in Supplementary Table 1, except for LRRK2, which is described in 
detail elsewhere49. 
aConstitutive brain-expressed exons only. 
bPRNP codons 1–144; see Fig. 3c for rationale.
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Extended Data Table 4 | Estimation of genetic prevalence for GoF genetic neurodegenerative diseases
Data sources were identified by PubMed and Google Scholar searches. Genetic prevalence was defined as the proportion of the population at birth carrying a mutation and destined to later 
develop disease, and estimated as described for each gene. The following references are cited in the table: refs. 36,41,58–74. 
aIt is important to consider how this figure relates to the penetrance of LRRK2 mutations, as LRRK2 variants appear to occupy a spectrum of penetrance75. Some variants exhibit Mendelian  
segregation with disease76,77, implying high risk; the G2019S variant is estimated to have approximately 32% penetrance78; and other common variants are risk factors with odds ratios of only 
around 1.2 estimated through genome-wide association studies (GWAS)79. The GWAS-implicated common variants were not included in the case series on which our estimate is based63,  
but G2019S does account for most cases in that series. Because the 0.03% estimate here is based on counting symptomatic cases rather than asymptomatic individuals, it will appropriately 
underestimate the number of G2019S carriers. In essence, in this calculation each G2019S carrier in the population only counts as 1/3 of a person, because they have only a 1/3 probability of 
developing a disease. It is therefore appropriate that our estimate of genetic prevalence (0.03%) is actually lower than double the allele frequency of G2019S in gnomAD (0.1%).
Extended Data Table 5 | Details of PRNP-truncating variants
Allele count for variants from the literature in Fig. 3c is the total number of definite or probable cases with sequencing performed in the studies cited in this table. The L234Pfs7X variant 
changes the C-terminal GPI signal of prion protein from SMVLFSSPPVILLISFLIFLIVGX to SMVPSPLHLX. This new sequence does not adhere to the known rules of GPI anchor attachment80: GPI 
signals must contain a 5–10-polar-residue spacer followed by 15–20 hydrophobic residues. Thus, this frameshifted prion protein would be predicted to be secreted and thus may be pathogenic, 
explaining the Alzheimer’s disease diagnosis in this individual. However, it is also possible that the new C-terminal sequence found here interferes with prion formation, and/or that this variant is 
incompletely penetrant, and that the diagnosis of Alzheimer’s disease in this individual is merely a coincidence. The following references are cited in the table: refs. 41,81–89.
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Policy information about availability of computer code
Data collection Analyses utilized Python 2.7.10 and R 3.5.1. Data and code sufficient to produce the plots and analyses in this paper are available at 
https://github.com/ericminikel/drug_target_lof
Data analysis Analyses utilized Python 2.7.10 and R 3.5.1. Data and code sufficient to produce the plots and analyses in this paper are available at 
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Analyses utilized Python 2.7.10 and R 3.5.1. Data and code sufficient to produce the plots and analyses in this paper are available at https://github.com/ericminikel/
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